PL2736487T5 - Nowe preparaty (trimetoksyfenyloamino)pirymidynylowe - Google Patents

Nowe preparaty (trimetoksyfenyloamino)pirymidynylowe

Info

Publication number: PL2736487T5
Authority: PL; Poland
Prior art keywords: trimethoxyphenylamino; pyrimidinyl; formulations; new; pyrimidinyl formulations
Prior art date: 2011-07-28

Application number

PL12759802.7T

Other languages

English (en)

Other versions

PL2736487T3 (pl

Inventor

Farhan Abdul Karim Alhusban

Ian Paul Gabbott

Bindhumadhavan GURURAJAN

Dawn SIEVWRIGHT

David Bradley Brook Simpson

Original Assignee

Rigel Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-28

Filing date

2012-07-26

Publication date

2025-01-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2736487(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-07-26 Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.

2019-06-28 Publication of PL2736487T3 publication Critical patent/PL2736487T3/pl

2025-01-27 Publication of PL2736487T5 publication Critical patent/PL2736487T5/pl

Links

-1 (trimethoxyphenylamino)pyrimidinyl Chemical group 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL12759802.7T 2011-07-28 2012-07-26 Nowe preparaty (trimetoksyfenyloamino)pirymidynylowe PL2736487T5 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161512621P	2011-07-28	2011-07-28
EP12759802.7A EP2736487B2 (en)	2011-07-28	2012-07-26	New (trimethoxyphenylamino)pyrimidinyl formulations
PCT/GB2012/051791 WO2013014454A1 (en)	2011-07-28	2012-07-26	New (trimethoxyphenylamino)pyrimidinyl formulations

Publications (2)

Publication Number	Publication Date
PL2736487T3 PL2736487T3 (pl)	2019-06-28
PL2736487T5 true PL2736487T5 (pl)	2025-01-27

Family

ID=46875902

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12759802.7T PL2736487T5 (pl)	2011-07-28	2012-07-26	Nowe preparaty (trimetoksyfenyloamino)pirymidynylowe

Country Status (27)

Country	Link
US (2)	US8771648B2 (pl)
EP (1)	EP2736487B2 (pl)
JP (1)	JP6019116B2 (pl)
KR (2)	KR102090440B1 (pl)
CN (1)	CN103826610B (pl)
AR (1)	AR087371A1 (pl)
AU (1)	AU2012288632B2 (pl)
BR (1)	BR112014001999B1 (pl)
CA (1)	CA2843138C (pl)
CY (1)	CY1122596T1 (pl)
DK (1)	DK2736487T4 (pl)
EA (1)	EA028432B1 (pl)
ES (1)	ES2710423T5 (pl)
FI (1)	FI2736487T4 (pl)
HR (1)	HRP20190186T4 (pl)
HU (1)	HUE042611T2 (pl)
LT (1)	LT2736487T (pl)
MX (1)	MX339685B (pl)
PL (1)	PL2736487T5 (pl)
PT (1)	PT2736487T (pl)
RS (1)	RS58433B2 (pl)
SI (1)	SI2736487T2 (pl)
SM (1)	SMT201900071T1 (pl)
TR (1)	TR201901792T4 (pl)
TW (1)	TW201311251A (pl)
UY (1)	UY34223A (pl)
WO (1)	WO2013014454A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE540041T1 (de) *	2006-11-21	2012-01-15	Rigel Pharmaceuticals Inc	Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
HRP20190186T4 (hr)	2011-07-28	2024-12-20	Rigel Pharmaceuticals, Inc.	Nove formulacije (trimetoksifenilamino)pirimidinila
PL3283551T3 (pl)	2015-04-02	2021-04-06	Stora Enso Oyj	Kompozycja aktywowanej ligniny, sposób jej wytwarzania oraz jej zastosowanie
WO2016172053A1 (en)	2015-04-24	2016-10-27	Rigel Pharmaceuticals, Inc.	Methods of treating ibrutinib-resistant disease
SE542795C2 (en)	2018-10-08	2020-07-07	Stora Enso Oyj	Process for preparing a resin
DK4178548T3 (da) *	2020-07-07	2024-08-19	Celgene Corp	Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL
WO2022017864A1 (en) *	2020-07-24	2022-01-27	Dsm Ip Assets B.V.	New fast dissolvable tablets

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
ES2291433T3 (es) †	2002-03-04	2008-03-01	Orbus Pharma Inc.	Composiciones de cefuroxima axetilo de liberacion rapida.
HRP20050089B1 (hr)	2002-07-29	2015-06-19	Rigel Pharmaceuticals	Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
WO2005012294A1 (en)	2003-07-30	2005-02-10	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
ATE506953T1 (de)	2003-08-07	2011-05-15	Rigel Pharmaceuticals Inc	2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
US20060051406A1 (en) *	2004-07-23	2006-03-09	Manjeet Parmar	Formulation of insoluble small molecule therapeutics in lipid-based carriers
EP1794135A1 (en) *	2004-09-27	2007-06-13	Amgen Inc.	Substituted heterocyclic compounds and methods of use
RU2361867C2 (ru) †	2004-11-23	2009-07-20	Донг Вха Фармасьютикал. Инд. Ко., Лтд.	Диметансульфонат n-гидрокси-4{5-[4-(5-изопропил-2-метил-1, 3-тиазол-4-ил)фенокси]пентокси}бензамидина
AU2006206458B2 (en) *	2005-01-19	2012-10-25	Rigel Pharmaceuticals, Inc.	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en)	2005-04-18	2012-07-24	Rigel Pharmaceuticals, Inc.	Methods of treating cell proliferative disorders
CA2631875A1 (en) *	2005-12-06	2007-10-04	Rigel Pharmaceuticals, Inc.	Formulation of insoluble small molecule therapeutics in lipid-based carriers
US7659280B2 (en) *	2006-02-17	2010-02-09	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
US20090048214A1 (en) *	2006-11-15	2009-02-19	Rigel Pharmaceuticals, Inc	Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
ATE540041T1 (de) *	2006-11-21	2012-01-15	Rigel Pharmaceuticals Inc	Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
WO2009003136A1 (en) *	2007-06-26	2008-12-31	Rigel Pharmaceuticals, Inc.	Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
US20090088371A1 (en) *	2007-08-28	2009-04-02	Rigel Pharmaceuticals, Inc.	Combination therapy with syk kinase inhibitor
UA102825C2 (ru) *	2007-11-07	2013-08-27	Райджел Фармасьютикалз, Инк.	Фармацевтическая композиция, полученная влажным гранулированием с использованием вещества, которое связывает воду
MX2010009159A (es)	2008-02-22	2010-09-14	Rigel Pharmaceuticals Inc	Uso de 2,4-pirimidindiaminas para el tratamiento de aterosclerosis.
UA108077C2 (xx) *	2009-07-02	2015-03-25		Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
EP2454265A2 (en)	2009-07-17	2012-05-23	Rigel Pharmaceuticals, Inc.	Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
JP5681723B2 (ja)	2009-11-20	2015-03-11	ライジェルファーマシューティカルズ，インコーポレイテッド	２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
CA2792278C (en)	2010-04-13	2019-05-14	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
HRP20190186T4 (hr) †	2011-07-28	2024-12-20	Rigel Pharmaceuticals, Inc.	Nove formulacije (trimetoksifenilamino)pirimidinila

2012
- 2012-07-26 HR HRP20190186TT patent/HRP20190186T4/hr unknown
- 2012-07-26 LT LTEP12759802.7T patent/LT2736487T/lt unknown
- 2012-07-26 PL PL12759802.7T patent/PL2736487T5/pl unknown
- 2012-07-26 JP JP2014522154A patent/JP6019116B2/ja active Active
- 2012-07-26 UY UY0001034223A patent/UY34223A/es unknown
- 2012-07-26 WO PCT/GB2012/051791 patent/WO2013014454A1/en not_active Ceased
- 2012-07-26 BR BR112014001999-1A patent/BR112014001999B1/pt active IP Right Grant
- 2012-07-26 AU AU2012288632A patent/AU2012288632B2/en active Active
- 2012-07-26 CA CA2843138A patent/CA2843138C/en active Active
- 2012-07-26 MX MX2014001065A patent/MX339685B/es active IP Right Grant
- 2012-07-26 RS RS20190146A patent/RS58433B2/sr unknown
- 2012-07-26 DK DK12759802.7T patent/DK2736487T4/da active
- 2012-07-26 KR KR1020197027074A patent/KR102090440B1/ko active Active
- 2012-07-26 SI SI201231519T patent/SI2736487T2/sl unknown
- 2012-07-26 HU HUE12759802A patent/HUE042611T2/hu unknown
- 2012-07-26 CN CN201280046605.3A patent/CN103826610B/zh active Active
- 2012-07-26 EP EP12759802.7A patent/EP2736487B2/en active Active
- 2012-07-26 EA EA201490363A patent/EA028432B1/ru unknown
- 2012-07-26 FI FIEP12759802.7T patent/FI2736487T4/fi active
- 2012-07-26 SM SM20190071T patent/SMT201900071T1/it unknown
- 2012-07-26 ES ES12759802T patent/ES2710423T5/es active Active
- 2012-07-26 KR KR1020147004810A patent/KR102024120B1/ko active Active
- 2012-07-26 TR TR2019/01792T patent/TR201901792T4/tr unknown
- 2012-07-26 PT PT12759802T patent/PT2736487T/pt unknown
- 2012-07-27 TW TW101127261A patent/TW201311251A/zh unknown
- 2012-07-27 US US13/559,805 patent/US8771648B2/en active Active
- 2012-07-27 AR ARP120102755A patent/AR087371A1/es not_active Application Discontinuation
2014
- 2014-05-29 US US14/290,494 patent/US8951504B2/en active Active
2019
- 2019-02-06 CY CY20191100159T patent/CY1122596T1/el unknown

Also Published As

Publication number	Publication date
UY34223A (es)	2013-02-28
AU2012288632B2 (en)	2017-08-17
JP6019116B2 (ja)	2016-11-02
KR20140058576A (ko)	2014-05-14
JP2014521630A (ja)	2014-08-28
HRP20190186T1 (hr)	2019-03-22
EP2736487A1 (en)	2014-06-04
US8771648B2 (en)	2014-07-08
TR201901792T4 (tr)	2019-03-21
TW201311251A (zh)	2013-03-16
SMT201900071T1 (it)	2019-02-28
DK2736487T4 (da)	2024-11-04
US20130058876A1 (en)	2013-03-07
EP2736487B1 (en)	2018-11-07
CY1122596T1 (el)	2021-01-27
ES2710423T5 (en)	2025-02-13
FI2736487T4 (fi)	2024-10-31
KR102090440B1 (ko)	2020-03-17
KR102024120B1 (ko)	2019-09-23
EP2736487B2 (en)	2024-08-28
SI2736487T2 (sl)	2025-06-30
US8951504B2 (en)	2015-02-10
CN103826610B (zh)	2017-08-04
RS58433B1 (sr)	2019-04-30
CN103826610A (zh)	2014-05-28
ES2710423T3 (es)	2019-04-25
PL2736487T3 (pl)	2019-06-28
BR112014001999B1 (pt)	2023-11-28
HK1198741A1 (en)	2015-06-05
EA028432B1 (ru)	2017-11-30
HRP20190186T4 (hr)	2024-12-20
DK2736487T3 (en)	2019-03-04
MX339685B (es)	2016-06-06
RS58433B2 (sr)	2025-01-31
CA2843138A1 (en)	2013-01-31
KR20190109576A (ko)	2019-09-25
HUE042611T2 (hu)	2019-07-29
US20140271493A1 (en)	2014-09-18
WO2013014454A1 (en)	2013-01-31
MX2014001065A (es)	2014-08-01
BR112014001999A2 (pt)	2017-02-21
EA201490363A1 (ru)	2014-06-30
PT2736487T (pt)	2019-02-13
CA2843138C (en)	2020-06-02
LT2736487T (lt)	2019-02-25
AU2012288632A1 (en)	2014-02-20
AR087371A1 (es)	2014-03-19
SI2736487T1 (sl)	2019-04-30

Publication	Publication Date	Title
TWI563077B (en)	2016-12-21	Cleaning formulations
ZA201306118B (en)	2014-04-30	Lyophilized formulations
IL232305A0 (en)	2014-06-30	pharmaceutical preparations
SI2753311T1 (sl)	2020-12-31	Formulacije antioksidanta
EP2729164A4 (en)	2015-05-06	FORMULATIONS STABILIZING PROTEINS
PL2736487T5 (pl)	2025-01-27	Nowe preparaty (trimetoksyfenyloamino)pirymidynylowe
GB201114725D0 (en)	2011-10-12	Ophthalmic formulations
AP2013006687A0 (en)	2013-01-31	Formulations
GB201110278D0 (en)	2011-08-03	Formulations
EP2782585A4 (en)	2015-08-05	ANTIVIRAL PREPARATIONS
GB201221125D0 (en)	2013-01-09	Pharmaceutial formulations
AP2013006689A0 (en)	2013-01-31	Formulations
GB201102795D0 (en)	2011-03-30	Formulations
GB201111578D0 (en)	2011-08-24	Pharmeutical formulations
GB201107626D0 (en)	2011-06-22	Formulations
GB201105410D0 (en)	2011-05-11	Formulations
GB201107627D0 (en)	2011-06-22	Formulations
GB201111013D0 (en)	2011-08-10	Formulations
GB201105360D0 (en)	2011-05-11	Formulations
GB201104049D0 (en)	2011-04-20	Formulations
GB201104048D0 (en)	2011-04-20	Formulations
GB201206178D0 (en)	2012-05-23	Formulations
GB201111577D0 (en)	2011-08-24	Pharmaceutical formulations
GB201103767D0 (en)	2011-04-20	Cosmetic formulations
GB201103769D0 (en)	2011-04-20	Cosmetic formulations